• Publications
  • Influence
EAU-ESTRO-SIOG Guidelines on Prostate Cancer. Part 1: Screening, Diagnosis, and Local Treatment with Curative Intent.
OBJECTIVE To present a summary of the 2016 version of the European Association of Urology (EAU) - European Society for Radiotherapy & Oncology (ESTRO) - International Society of Geriatric OncologyExpand
  • 1,807
  • 129
  • PDF
EAU guidelines on prostate cancer. Part 1: screening, diagnosis, and treatment of clinically localised disease.
OBJECTIVE Our aim was to present a summary of the 2010 version of the European Association of Urology (EAU) guidelines on the screening, diagnosis, and treatment of clinically localised cancer of theExpand
  • 1,299
  • 95
  • PDF
Guidelines on Prostate Cancer
The introduction of an effective blood test, prostate specific antigen (PSA), has made it possible to diagnose more and more men in an earlier stage where they can be offered potentially curativeExpand
  • 825
  • 81
  • PDF
EAU guidelines on prostate cancer. part 1: screening, diagnosis, and local treatment with curative intent-update 2013.
CONTEXT The most recent summary of the European Association of Urology (EAU) guidelines on prostate cancer (PCa) was published in 2011. OBJECTIVE To present a summary of the 2013 version of the EAUExpand
  • 1,637
  • 70
  • PDF
Comprehensive Molecular Characterization of Muscle-Invasive Bladder Cancer
We report a comprehensive analysis of 412 muscle-invasive bladder cancers characterized by multiple TCGA analytical platforms. Fifty-eight genes were significantly mutated, and the overall mutationalExpand
  • 848
  • 66
MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer
There have been no major advances for the treatment of metastatic urothelial bladder cancer (UBC) in the last 30 years. Chemotherapy is still the standard of care. Patient outcomes, especially forExpand
  • 1,738
  • 60
  • PDF
EAU-ESTRO-SIOG Guidelines on Prostate Cancer. Part II: Treatment of Relapsing, Metastatic, and Castration-Resistant Prostate Cancer.
OBJECTIVE To present a summary of the 2016 version of the European Association of Urology (EAU) - European Society for Radiotherapy & Oncology (ESTRO) - International Society of Geriatric OncologyExpand
  • 866
  • 57
  • PDF
Pembrolizumab as Second‐Line Therapy for Advanced Urothelial Carcinoma
Background Patients with advanced urothelial carcinoma that progresses after platinum‐based chemotherapy have a poor prognosis and limited treatment options. Methods In this open‐label,Expand
  • 1,341
  • 56
  • PDF
EAU guidelines on prostate cancer. Part II: Treatment of advanced, relapsing, and castration-resistant prostate cancer.
OBJECTIVE To present a summary of the 2013 version of the European Association of Urology (EAU) guidelines on the treatment of advanced, relapsing, and castration-resistant prostate cancer (CRPC). Expand
  • 604
  • 55
  • PDF
[EAU guidelines on prostate cancer. Part II: treatment of advanced, relapsing, and castration-resistant prostate cancer].
OBJECTIVES Our aim is to present a summary of the 2010 version of the European Association of Urology (EAU) guidelines on the treatment of advanced, relapsing, and castration-resistant prostateExpand
  • 612
  • 44
  • PDF
...
1
2
3
4
5
...